Biomea Fusion Inc (BMEA)
5.64
-0.17
(-2.93%)
USD |
NASDAQ |
Jun 14, 16:00
5.65
+0.01
(+0.18%)
After-Hours: 20:00
Biomea Fusion Cash from Operations (TTM): -104.58M for March 31, 2024
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
March 31, 2024 | -104.58M |
December 31, 2023 | -96.59M |
September 30, 2023 | -93.96M |
June 30, 2023 | -86.85M |
March 31, 2023 | -76.47M |
December 31, 2022 | -62.42M |
September 30, 2022 | -58.12M |
Date | Value |
---|---|
June 30, 2022 | -50.31M |
March 31, 2022 | -41.36M |
December 31, 2021 | -35.44M |
September 30, 2021 | -22.28M |
June 30, 2021 | -14.39M |
March 31, 2021 | -8.282M |
December 31, 2020 | -4.459M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-104.58M
Minimum
Mar 2024
-4.459M
Maximum
Dec 2020
-53.96M
Average
-54.21M
Median
Cash from Operations (TTM) Benchmarks
Geron Corp | -183.63M |
Poseida Therapeutics Inc | -69.30M |
Asensus Surgical Inc | -60.39M |
Geovax Labs Inc | -27.09M |
Cartesian Therapeutics Inc | -58.31M |